Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

240.65
+3.301.39%
Post-market: 240.650.00000.00%17:35 EST
Volume:559.29K
Turnover:133.29M
Market Cap:14.85B
PE:-54.47
High:241.79
Open:233.87
Low:233.00
Close:237.35
52wk High:248.60
52wk Low:124.06
Shares:61.70M
Float Shares:60.08M
Volume Ratio:0.61
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4176
EPS(LYR):-4.4176
ROE:-818.43%
ROA:-6.86%
PB:-78.49
PE(LYR):-54.47

Loading ...

RBC Raises Price Target on Ascendis Pharma to $250 From $245, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 20

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)

TIPRANKS
·
Jan 20

Ascendis Pharma a/S : Leerink Partners Raises Target Price to $290 From $225

THOMSON REUTERS
·
Jan 20

Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results

Simply Wall St.
·
Jan 17

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Rise 2% for Week

MT Newswires Live
·
Jan 17

Ascendis Pharma price target raised to $246 from $242 at BofA

TIPRANKS
·
Jan 12

Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026

Reuters
·
Jan 10

Ascendis Pharma A/S outlines strategy to expand rare disease portfolio and target blockbuster revenues

Reuters
·
Jan 10

Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program

Reuters
·
Jan 10

Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating

MT Newswires Live
·
Jan 10

Ascendis Pharma a/S : Wells Fargo Raises Target Price to $322 From $297

THOMSON REUTERS
·
Jan 09

Ascendis Pharma A/S Releases Data on TransCon CNP and TransCon hGH Combination Therapy in Achondroplasia

Reuters
·
Jan 09

Ascendis Pharma announces topline results from Week 52 of COACH trial

TIPRANKS
·
Jan 09

Ascendis Pharma Reports Positive 52-Week Results from COACH Trial in Pediatric Achondroplasia

Reuters
·
Jan 09

RBC Raises Price Target on Ascendis Pharma to $245 From $240, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 08

European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week

MT Newswires Live
·
Dec 27, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live
·
Dec 19, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week

MT Newswires Live
·
Dec 13, 2025

Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'

Benzinga_recent_news
·
Dec 09, 2025

Biotech Is Healthier Than Investors Think -- Barron's

Dow Jones
·
Dec 06, 2025